Unity Biotechnology doses first patients in Phase 2 ASPIRE study of UBX1325

UNITY Biotechnology, announced that the first patients have been dosed in the Phase 2 ASPIRE study of UBX1325, a Bcl-xL inhibitor being evaluated head-to-head against standard of care anti-VEGF in patients with diabetic macular edema. “Many patients with DME have poor vision despite frequent anti-VEGF injections and there is an urgent need to develop new treatment options for such patients,” said Anirvan Ghosh, Ph.D., chief executive officer of UNITY. “There has been great interest from the physician community in the therapeutic potential of UBX1325, which is based on a novel senolytic mechanism of action, and we are excited to have dosed our first patients in the ASPIRE study. We look forward to sharing initial results from the study in the fourth quarter of 2024.”